{
    "clinical_study": {
        "@rank": "119371", 
        "acronym": "ANTI-ACNE", 
        "arm_group": [
            {
                "arm_group_label": "not in therapy (GROUP 1)", 
                "description": "A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0)."
            }, 
            {
                "arm_group_label": "in therapy (GROUP 2)", 
                "description": "A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary end point of the study is the clinical and non-invasive instrumental evaluation of\n      the activity of P-3075 cream on subjects with acne: 20 subjects with a mild/moderate grade\n      and 20 subjects with a moderately severe/severe grade, according to Cunliffe'\n      classification.\n\n      Secondary end-points are the cosmetic acceptability and efficacy evaluation by the\n      volunteers and the local tolerability assessed by the investigator and the subjects."
        }, 
        "brief_title": "Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acne", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "detailed_description": {
            "textblock": "This is an open controlled clinical trial. The product will be applied for a period of 4\n      weeks and 3 visits will be performed: a baseline visit (T0), an intermediate visit after 2\n      weeks (T2) and a final visit after 4 week-treatment (T4).\n\n      The subjects will be enrolled and divided in 2 groups according to their acne grade (20\n      subjects with mild/moderate grade and 20 subjects with moderately severe/severe), a\n      concomitant therapy is allowed only for volunteers with acne moderately severe/severe.\n\n      Each volunteer, fulfilling the inclusion criteria, will perform a cosmetic treatment with\n      the study product on all the face, for 4 weeks.\n\n      A fixed quantity of the medical device will be applied on the face twice a day, in the\n      morning and in the evening (always at the same hour), with a mild massage according to the\n      instructions received by the investigator during the baseline visit (T0). Group 2 will\n      continue also the standardised treatment with topical or systemic retinoids, benzoyl\n      peroxide, clindamycin or AHA until the end of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  both genders;\n\n          -  age > 16 years old;\n\n          -  acne of mild/moderate grade, not in therapy (GROUP 1);\n\n          -  acne of moderately severe/severe grade, in therapy with topical or systemic\n             retinoids, benzoyl peroxide, clindamycin or AHA (GROUP 2);\n\n          -  accepting to follow the instructions received by the investigator;\n\n          -  available to return to the study centre at the protocol visits;\n\n          -  accepting to not change the normal life habits regarding: food, physical activity,\n             face   cleansing;\n\n          -  accepting  not  to receive  any other drug/cosmetic treatment able to interfere with\n             the study results;\n\n          -  accepting to sign the informed consent form (under 18 years the signature of both\n             parents is required).\n\n        Exclusion Criteria:\n\n          -  Pregnancy (only for female subjects) - for subjects belonging to Group 2, a control\n             pregnancy test could be required at T2 and T4 in case of assumption of an anti-acne\n             drug with potential teratogenic effects; these subjects must confirm to use adequate\n             contraceptive precautions in order to avoid pregnancies;\n\n          -  lactation (only for female subjects);\n\n          -  subjects whose insufficient adhesion to the study protocol is expected;\n\n          -  subjects who changed the anti-acne therapy during the 2 months prior to the study\n             inclusion;\n\n          -  concomitant participation in other studies or in the last 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The study will be conducted on volunteers of both genders, aged > 16 years old: 20\n        subjects presenting acne of mild/moderate grade not in therapy (GROUP 1) and 20 subjects\n        presenting acne of moderately severe/severe grade in therapy with topical or systemic\n        retinoids, benzoyl peroxide, clindamycin or AHA (GROUP 2)."
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948570", 
            "org_study_id": "E0113"
        }, 
        "intervention_browse": {
            "mesh_term": "Benzoyl Peroxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "acne,comedones, oily skin", 
        "lastchanged_date": "September 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Monza", 
                    "country": "Italy", 
                    "state": "MB", 
                    "zip": "20900"
                }, 
                "name": "DermIng S.r.l"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "2", 
        "official_title": "Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment", 
        "overall_official": {
            "affiliation": "Derming SRL", 
            "last_name": "Adele Sparavigna, Physician", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Visual evaluations (comedones, dryness, desquamation, papules, pustoles, microcystis) Tissue dielectric constant (superficial and deep hydration), sebumetry and optical colorimetry (skin colour), follicular biopsy, sebutape image analysis", 
            "measure": "clinical and non-invasive instrumental evaluation of the activity of P-3075 cream on subjects with acne", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948570"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Derming SRL", 
            "investigator_full_name": "Adele Sparavigna", 
            "investigator_title": "Dermatologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "subjects' self assessment", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "source": "Derming SRL", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Derming SRL", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Months", 
        "verification_date": "September 2013"
    }
}